CM Life Sciences II To Combine With Proteomics SomaLogic In Latest SPAC Deal

The SPAC deal between CM Life Sciences II and SomaLogic is valued at $1.25bn.

SPAC

CM Life Sciences II, a special-purpose acquisitions company (SPAC) focused on life sciences, announced on 22 March it has signed an agreement to merge with Boulder, CO-based SomaLogic, Inc., a proteomics technology platform company.

CM Life Sciences, led by affiliates of institutional investors Casdin Capital LLC and Corvex Management, could combine with SomaLogic, a deal that is estimated to be worth around $1.25bn, according...

More from Financing

More from Business